Brought to you by 
Dicerna closes its $13mm Series A round; adds $8.4mm
05 Aug 2008
Executive Summary
Dicerna Pharmaceuticals (RNAi therapeutics) has raised $13mm through the closing of its Series A venture round. Oxford Bioscience Partners and Skyline Ventures led the financing and will each put a member on the company's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dicerna closes its $13mm Series A round; adds $8.4mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice